Sponsor Overview
Explore verified public information about Bionic Sight, Inc.'s expanded access programs, compassionate use policies, and patient eligibility pathways. This report aggregates official statements, independent research, and regulatory data to help patients, providers, and sponsors collaborate efficiently.
Unique references curated across 0 content categories.
ClinicalTrials.gov data sources power this status.
Dataset refreshed continuously through Right2Hope ETL pipelines.
Expanded Access Intelligence
No evidence found.
Reagan-Udall Foundation Insights
Available Therapies via Single-Patient EA Bionic Sight’s technology focuses on restoring sight to patients with advanced stage blindness due to retinal degenerative diseases. Our lead product, BS01, is currently being investigated in a Phase I/II, open label study in patients with retinitis pigmentosa. Currently, Bionic Sight does not offer an expanded access program for BS01 for retinitis pigmentosa. Given the current stage of our development program, we believe that participation in our clinical trial is the most appropriate way to access our investigational therapy. We believe that access to BS01 should be limited to controlled clinical trials until such time as its safety and efficacy have been determined and confirmed by regulatory authorities. Consistent with the 21st Century Cures Act, Bionic Sight may revise this policy at any time. Last updated: January 2025
Partner with Right2Hope
Right2Hope helps sponsors translate regulatory programs into actionable patient access pathways. Connect with our team to publish new programs, streamline intake workflows, or align with providers seeking compassionate use options.